Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
| Status: | Terminated |
|---|---|
| Conditions: | Cancer, Cancer, Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/10/2018 |
| Start Date: | May 2013 |
| End Date: | December 1, 2015 |
RT-054: A Phase I Study of Neoadjuvant Hypofractionated Chemoradiation Plus Radiosurgical Boost for Patients With Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer
This phase I trial studies the side effects and best dose of radiosurgery boost following
chemoradiation in treating patients with locally advanced pancreatic cancer that may or may
not be removed by surgery. Drugs used in chemotherapy work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Radiation therapy uses high-energy x-rays to kill tumor cells. Radiosurgery can send x-rays
directly to the tumor and cause less damage to normal tissue. Giving chemotherapy and
radiation therapy together with radiosurgery may kill more tumor cells and allow doctors to
save the part of the body where the cancer started
chemoradiation in treating patients with locally advanced pancreatic cancer that may or may
not be removed by surgery. Drugs used in chemotherapy work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Radiation therapy uses high-energy x-rays to kill tumor cells. Radiosurgery can send x-rays
directly to the tumor and cause less damage to normal tissue. Giving chemotherapy and
radiation therapy together with radiosurgery may kill more tumor cells and allow doctors to
save the part of the body where the cancer started
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) of a radiosurgery boost added to
hypofractionated chemoradiation in patients with borderline resectable or unresectable
pancreatic cancer.
SECONDARY OBJECTIVES:
I. To determine the effect of a radiosurgery boost added to hypofractionated chemoradiation
on surgical morbidity (specifically, healing of the surgical anastomoses and abdominal wounds
and late hemorrhage from blood vessels in the field) in patients with advanced borderline
resectable (BLR) or unresectable pancreatic cancer.
II. To evaluate the utility of diffusion-weighted magnetic resonance imaging (MRI) as an
assessment of treatment response after chemoradiation followed by radiosurgery.
III. To determine the feasibility of collecting tissue for immunohistochemistry (IHC)
analysis via endoscopic ultrasound or computed tomography (CT)-guided fine needle aspiration.
IV. To utilize pathologic response rates in dose escalated regions, hypofractionated regions,
and the dose gradient region in between to better characterize the radiobiologic response of
pancreatic cancer to radiation dose escalation.
OUTLINE: This is a dose-escalation study of radiosurgery.
Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes once weekly and
undergo hyperfractionated intensity-modulated radiation therapy (IMRT) 5 days a week in weeks
1-3. Patients then undergo a single fraction of radiosurgery boost in week 5 and then receive
gemcitabine hydrochloride IV over 30 minutes once weekly in weeks 6-8. Treatment continues in
the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 2 years, and then annually thereafter.
I. To determine the maximum tolerated dose (MTD) of a radiosurgery boost added to
hypofractionated chemoradiation in patients with borderline resectable or unresectable
pancreatic cancer.
SECONDARY OBJECTIVES:
I. To determine the effect of a radiosurgery boost added to hypofractionated chemoradiation
on surgical morbidity (specifically, healing of the surgical anastomoses and abdominal wounds
and late hemorrhage from blood vessels in the field) in patients with advanced borderline
resectable (BLR) or unresectable pancreatic cancer.
II. To evaluate the utility of diffusion-weighted magnetic resonance imaging (MRI) as an
assessment of treatment response after chemoradiation followed by radiosurgery.
III. To determine the feasibility of collecting tissue for immunohistochemistry (IHC)
analysis via endoscopic ultrasound or computed tomography (CT)-guided fine needle aspiration.
IV. To utilize pathologic response rates in dose escalated regions, hypofractionated regions,
and the dose gradient region in between to better characterize the radiobiologic response of
pancreatic cancer to radiation dose escalation.
OUTLINE: This is a dose-escalation study of radiosurgery.
Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes once weekly and
undergo hyperfractionated intensity-modulated radiation therapy (IMRT) 5 days a week in weeks
1-3. Patients then undergo a single fraction of radiosurgery boost in week 5 and then receive
gemcitabine hydrochloride IV over 30 minutes once weekly in weeks 6-8. Treatment continues in
the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 2 years, and then annually thereafter.
Inclusion Criteria:
- Patients must have histologically or cytologically-confirmed pancreatic adenocarcinoma
- For the initial dose escalation study, patients must have locally advanced /
unresectable pancreatic cancer; these are defined as follows:
- No distant metastases
- Hepatic artery encasement
- Superior mesenteric artery (SMA) encasement > 180 degrees
- Any celiac axis abutment
- Unreconstructable superior mesenteric vein (SMV)/portal occlusion
- Aortic invasion or encasement
- Metastases to lymph nodes beyond the field of resection
- For the expansion phase, patients must have borderline resectable or locally advanced
/ unresectable pancreatic cancer; these are defined as follows:
- No distant metastases
- At least 45 degree abutment of the hepatic artery or SMA
- Any celiac axis abutment
- Near complete occlusion of the SMV or portal vein
- Unreconstructable or reconstructible SMV/portal occlusion
- Aortic invasion or encasement
- Metastases to lymph nodes beyond the field of resection
- Patients must have evaluable disease
- Women of childbearing potential must be non-pregnant (negative pregnancy test within
72 hours prior to radiation simulation, postmenopausal woman must have been
amenorrheic for at least 12 months to be considered of non-childbearing potential) and
nonlactating, and men and women must be willing to exercise an effective form of birth
control (abstinence/contraception) while on study and for 3 months after therapy
completed
- Eastern Cooperative Oncology Group (ECOG) performance status determined to be between
0 and 1
- Absolute neutrophil count (ANC) >= 1,500/ul
- Platelets (PLT) >= 100,000/ul
- Subjects must sign a written informed consent and Health Insurance Portability and
Accountability Act (HIPAA) consent prior to performance of study-specific procedures
or assessments and must be willing to comply with treatment and follow up
- Bilirubin less then 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN
- Serum creatinine < 1.5 x ULN
Exclusion Criteria:
- Patients who have had any prior therapy for pancreatic cancer
- Concurrent chemotherapy or biologic therapy
- A history of ataxia telangiectasia or other documented history of radiation
hypersensitivity
- Scleroderma or active connective tissue disease
- Active inflammatory bowel disease
- Serious, active infections requiring treatment with IV antibiotics
- Uncontrolled intercurrent illness including, but not limited to, psychiatric
illness/social situations that would limit compliance with study requirements
We found this trial at
1
site
Click here to add this to my saved trials
